Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-8.83 Insider Own4.40% Shs Outstand76.43M Perf Week3.72%
Market Cap13.25B Forward P/E- EPS next Y-2.34 Insider Trans-4.03% Shs Float74.06M Perf Month5.62%
Income-655.90M PEG- EPS next Q-1.71 Inst Own95.10% Short Float14.40% Perf Quarter55.23%
Sales407.50M P/S32.53 EPS this Y-77.80% Inst Trans0.05% Short Ratio11.52 Perf Half Y28.24%
Book/sh14.98 P/B11.27 EPS next Y55.60% ROA-31.90% Target Price194.76 Perf Year9.45%
Cash/sh27.65 P/C6.11 EPS next 5Y-0.20% ROE-64.70% 52W Range72.05 - 172.70 Perf YTD30.82%
Dividend- P/FCF50.00 EPS past 5Y-23.40% ROI-47.10% 52W High-2.25% Beta1.91
Dividend %- Quick Ratio7.70 Sales past 5Y108.10% Gross Margin86.00% 52W Low134.30% ATR6.03
Employees743 Current Ratio8.30 Sales Q/Q30.70% Oper. Margin- RSI (14)60.99 Volatility3.15% 3.60%
OptionableYes Debt/Eq0.00 EPS Q/Q78.60% Profit Margin- Rel Volume0.47 Prev Close169.96
ShortableYes LT Debt/Eq0.60 EarningsMay 06 AMC Payout- Avg Volume925.39K Price168.81
Recom1.70 SMA202.90% SMA5012.84% SMA20043.71% Volume433,093 Change-0.68%
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Jul-10-20 08:47PM  
Jul-02-20 08:21AM  
07:00AM  
Jun-30-20 06:15PM  
08:30AM  
Jun-29-20 10:06AM  
Jun-26-20 08:30AM  
Jun-23-20 04:05PM  
10:27AM  
05:43AM  
Jun-22-20 08:00AM  
Jun-18-20 08:30AM  
Jun-16-20 12:00PM  
11:30AM  
Jun-15-20 04:02PM  
11:00AM  
Jun-09-20 10:34AM  
08:59AM  
Jun-08-20 04:15PM  
09:47AM  
08:55AM  
Jun-05-20 04:05PM  
11:31AM  
Jun-02-20 08:57PM  
05:00PM  
May-29-20 06:28PM  
01:50AM  
May-28-20 11:30AM  
May-18-20 11:38AM  
10:49AM  
May-15-20 04:15PM  
03:37PM  
10:03AM  
May-14-20 10:53AM  
May-13-20 02:56PM  
May-12-20 04:30PM  
07:52AM  
May-11-20 07:00AM  
May-07-20 11:41AM  
07:31AM  
07:19AM  
May-06-20 06:15PM  
04:05PM  
Apr-30-20 06:52PM  
Apr-29-20 08:30AM  
06:15AM  
Apr-28-20 08:30AM  
Apr-15-20 08:34AM  
Apr-14-20 07:29AM  
Apr-08-20 02:19PM  
06:00AM  
Mar-31-20 06:06PM  
Mar-27-20 11:31AM  
Mar-24-20 02:20AM  
Mar-11-20 07:57PM  
Feb-28-20 06:20PM  
12:10PM  
Feb-27-20 10:47AM  
08:30AM  
Feb-26-20 06:15PM  
04:05PM  
Feb-19-20 12:31PM  
08:30AM  
Feb-18-20 08:33AM  
Feb-10-20 02:09PM  
Feb-04-20 11:28AM  
Feb-03-20 03:31AM  
Jan-31-20 06:16PM  
05:00AM  
Jan-30-20 07:19AM  
Jan-28-20 02:36PM  
Jan-23-20 05:15PM  
02:25PM  
Jan-22-20 11:48AM  
Jan-20-20 08:54AM  
Jan-16-20 01:10PM  
Jan-13-20 01:56PM  
08:30AM  
Jan-10-20 10:08AM  
Jan-09-20 09:12PM  
Jan-06-20 08:30AM  
Dec-31-19 06:06PM  
Dec-26-19 11:10AM  
Dec-24-19 12:15PM  
11:10AM  
09:15AM  
09:04AM  
08:57AM  
07:30AM  
Dec-23-19 04:22PM  
01:15PM  
10:11AM  
08:48AM  
08:44AM  
01:15AM  
01:00AM  
Dec-19-19 10:27AM  
Dec-18-19 08:38AM  
Dec-16-19 06:04PM  
04:09PM  
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mahatme SandeshEVP, CFO & CBOJul 08Option Exercise19.693,80674,94120,260Jul 09 08:00 PM
Howton David TEVP, General CounselJun 22Option Exercise25.76105,1222,708,440136,993Jun 22 09:17 PM
Howton David TEVP, General CounselJun 22Sale170.88105,12217,962,83131,871Jun 22 09:17 PM
Wigzell Hans Lennart RudolfDirectorMay 20Option Exercise10.085,00050,40018,792May 22 08:00 PM
Wigzell Hans Lennart RudolfDirectorMay 20Sale150.645,000753,21013,792May 22 08:00 PM
Barry RichardDirectorMay 15Sale141.2630,0004,237,9463,159,140May 15 09:02 PM
Wigzell Hans Lennart RudolfDirectorMar 04Option Exercise8.465,00042,30018,792Mar 06 08:01 PM
Wigzell Hans Lennart RudolfDirectorMar 04Sale116.895,000584,45013,792Mar 06 08:01 PM
Mahatme SandeshEVP, CFO & CBODec 13Option Exercise28.88125,0003,610,443155,179Dec 17 08:00 PM
Howton David TEVP, General CounselDec 13Option Exercise21.4878,0001,675,439103,171Dec 17 08:01 PM
Cumbo AlexanderEVP, Chief Commercial OfficerDec 13Option Exercise23.7032,706775,23243,867Dec 17 08:02 PM
Cumbo AlexanderEVP, Chief Commercial OfficerDec 13Sale125.5042,0005,271,0001,867Dec 17 08:02 PM
Howton David TEVP, General CounselDec 13Sale125.5078,0009,789,00025,171Dec 17 08:01 PM
Mahatme SandeshEVP, CFO & CBODec 13Sale125.50125,00015,687,50030,179Dec 17 08:00 PM
Howton David TEVP, General CounselNov 22Option Exercise16.1334,272552,66736,993Nov 26 08:01 PM
Howton David TEVP, General CounselNov 22Sale105.0025,0002,625,00011,993Nov 26 08:01 PM
Barry RichardDirectorSep 13Buy87.493,309289,5043,187,065Sep 16 08:00 AM
Barry RichardDirectorSep 12Buy87.491,691147,9503,183,756Sep 16 08:00 AM
BONNEY MICHAEL WDirectorSep 09Buy86.742,000173,4807,051Sep 09 02:18 PM
BEHRENS M KATHLEENDirectorSep 06Buy87.982,500219,950125,667Sep 06 02:13 PM
BEHRENS M KATHLEENDirectorSep 05Option Exercise7.805,00039,000123,167Sep 06 02:13 PM
Mahatme SandeshEVP, CFO & CBOAug 21Option Exercise23.85100,0002,385,000130,179Aug 22 07:20 PM
Barry RichardDirectorAug 20Buy99.325,000496,5933,182,065Aug 20 05:43 PM
Mahatme SandeshEVP, CFO & CBOAug 15Option Exercise24.739,754241,23230,179Aug 15 04:33 PM
Barry RichardDirectorAug 14Buy122.503,700453,2503,177,065Aug 14 04:38 PM
Barry RichardDirectorAug 12Buy122.501,300159,2503,173,365Aug 13 04:31 PM
INGRAM DOUGLAS SPresident & CEOAug 12Buy123.0716,2522,000,160432,197Aug 12 05:48 PM